Olaparib and advanced ovarian cancer: Summary of the past and looking into the future.
BRCA
PARP
olaparib (LynparzaTM)
ovarian cancer
target therapy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
02
2023
accepted:
11
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Ovarian cancer (OC) is women's eighth most common cancer, bearing the highest mortality rates of all female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC as a maintenance post platinum-based chemotherapy. Olaparib is the first PARPi developed for this disease. Results from Study 42, Study 19, SOLO2, OPINION, SOLO1, and PAOLA-1 clinical trials, led to the FDA and EMA approval of olaparib for the maintenance treatment of women with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer without platinum progression: in the platinum-sensitive recurrent OC; in the newly diagnosed setting in case Breast Cancer (BRCA) mutations and, in combination with bevacizumab, in case of BRCA mutation or deficiency of homologous recombination genes. In this review, we synthetized olaparib's pharmacokinetic and pharmacodynamic properties and its use in special populations. We summarized the efficacy and safety of the studies leading to the current approvals and discussed the future developments of this agent.
Identifiants
pubmed: 37153769
doi: 10.3389/fphar.2023.1162665
pii: 1162665
pmc: PMC10160416
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1162665Informations de copyright
Copyright © 2023 Maiorano, Maiorano and Maiello.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gynecol Oncol. 2017 Dec;147(3):509-513
pubmed: 29037805
Eur J Cancer. 2007 Sep;43(14):2124-33
pubmed: 17714938
Ann Oncol. 2021 Aug;32(8):1048-1050
pubmed: 34107345
Cancer Res. 2005 Dec 15;65(24):11597-604
pubmed: 16357170
Lancet Oncol. 2019 Jan;20(1):e15-e28
pubmed: 30614472
Eur J Cancer. 2022 Oct;174:221-231
pubmed: 36067615
Clin Pharmacokinet. 2019 Sep;58(9):1165-1174
pubmed: 30877569
BMJ Open. 2021 Jan 15;11(1):e041463
pubmed: 33452192
Trends Cell Biol. 2019 Oct;29(10):820-834
pubmed: 31421928
N Engl J Med. 1996 Jan 4;334(1):1-6
pubmed: 7494563
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Gynecol Oncol. 2022 Mar;164(3):505-513
pubmed: 35063281
Cancer Chemother Pharmacol. 2016 Sep;78(3):525-31
pubmed: 27422301
Xenobiotica. 2018 Jun;48(6):555-564
pubmed: 28657402
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
J Clin Oncol. 2019 Jun 1;37(16):1380-1390
pubmed: 31002578
J Clin Oncol. 2011 Aug 1;29(22):3008-15
pubmed: 21709188
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Adv Ther. 2018 Nov;35(11):1945-1964
pubmed: 30324586
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Int J Gynecol Cancer. 2022 Oct 13;:
pubmed: 36229080
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
J Clin Oncol. 2022 Jul 1;40(19):2138-2147
pubmed: 35290101
Ann Oncol. 2016 Jun;27(6):1013-1019
pubmed: 26961146
J Clin Oncol. 2000 Sep;18(17):3084-92
pubmed: 10963636
Int J Mol Sci. 2022 Mar 31;23(7):
pubmed: 35409229
Cancer Sci. 2012 Mar;103(3):504-9
pubmed: 22145984
Cancer Chemother Pharmacol. 2019 May;83(5):963-974
pubmed: 30887180
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279
pubmed: 32398324
Cancer Res. 2015 Feb 15;75(4):628-34
pubmed: 25634215
Gynecol Oncol. 2022 Feb;164(2):254-264
pubmed: 34952708
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
Clin Cancer Res. 2013 Oct 1;19(19):5485-93
pubmed: 23922302
J Natl Cancer Inst. 2000 May 3;92(9):699-708
pubmed: 10793106
Nat Med. 2013 Nov;19(11):1381-8
pubmed: 24202391
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
Front Pharmacol. 2023 Jan 23;13:979873
pubmed: 36756144
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
J Clin Oncol. 2010 May 20;28(15):2512-9
pubmed: 20406929
J Med Chem. 2021 Oct 14;64(19):14498-14512
pubmed: 34570508
J Clin Oncol. 2004 Aug 1;22(15):3120-5
pubmed: 15284263
Future Sci OA. 2019 Jan 10;5(2):FSO370
pubmed: 30820349
Clin Pharmacokinet. 2019 May;58(5):615-625
pubmed: 30357650
Gynecol Oncol. 2016 Feb;140(2):199-203
pubmed: 26723501
Target Oncol. 2016 Jun;11(3):401-15
pubmed: 27169564
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Neoplasia. 2014 Apr;16(4):343-53.e1-2
pubmed: 24862760
Br J Cancer. 2012 Jan 31;106(3):468-74
pubmed: 22223088
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
J Clin Oncol. 2023 Jan 20;41(3):609-617
pubmed: 36082969
Gynecol Oncol. 2022 Mar;164(3):498-504
pubmed: 35063276
Gynecol Oncol. 2022 Apr;165(1):14-22
pubmed: 35177277
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Gynecol Oncol. 2022 Apr;165(1):40-48
pubmed: 35115180
Oncologist. 2021 Jan;26(1):e164-e172
pubmed: 33017510
Br J Clin Pharmacol. 2020 Sep;86(9):1807-1818
pubmed: 32227355
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Clin Cancer Res. 2022 Oct 3;28(19):4186-4193
pubmed: 35917514
Clin Cancer Res. 2022 Nov 1;28(21):4724-4736
pubmed: 35929986